 | | Vol. 14.22 – 16 June, 2022 |
| |
|
|
| Scientists performed a comprehensive study of noncoding regulatory variants at the NTN4 locus and NTN4 gene in breast cancer etiology.
[Science Advances] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The combination of AURK and WEE1 inhibitors yielded synergistic cell death selectively in RB-deleted ER+ breast cancer cells via apoptosis and yielded profound disease control in vivo.
[Oncogene] |
|
|
|
| Investigators showed that the Suppressor of fused homolog (SUFU), a critical component in Hedgehog signaling, regulated ferroptosis sensitivity of breast cancer cells.
[iScience] |
|
|
|
| RhoBTB3 mRNA levels were significantly up-regulated in breast cancer tissues as compared to in adjacent normal tissues and RhoBTB3 expression was found to be associated with Col1a1 expression.
[Molecules and Cells] |
|
|
|
| The authors showed that an RNA-binding protein, PSPC1, played a crucial role in ER-positive breast cancer growth through post-transcriptional gene regulation.
[Scientific Reports] |
|
|
|
| A huge increase of HERC5 expression was found in MCF-7 and MDA-MB-231 cells, knockdown of which repressed the cell proliferation and migration.
[Life Sciences] |
|
|
|
| Scientists abrogated lipocalin 2 (Lcn2) expression in MDA-MB-231 breast cancer cells using the CRISPR/Cas9 technology and evaluated its effect on cellular proliferation, migration, and ferroptotic cell death.
[Life Sciences] |
|
|
|
| Target genes were characterized for their expression in the TNBC cell lines to prove the combinatorial effect of JQ1 and GSK2801.
[BMC Cancer] |
|
|
|
|
| Investigators provide cellular and molecular insights into the visfatin-mediated cellular plasticity programs such as epithelial to mesenchymal transition and endothelial to mesenchymal transition, and stemness-associated changes in breast cancer cells.
[Life Sciences] |
|
|
|
|
| Daiichi Sankyo announced that the first patient was dosed in the global TROPION-Breast02 Phase III trial evaluating the efficacy and safety of datopotamab deruxtecan versus investigator’s choice of chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC.
[Daiichi Sankyo] |
|
|
|
| Immunicom, Inc. has been awarded $2 million by the National Cancer Institute (NCI) and National Institutes of Health (NIH) to initiate its first US-based clinical trial at the Baylor College of Medicine in Houston, Texas.
[Immunicom, Inc.] |
|
|
|
| The Breast Cancer Society of Canada has announced $250,000 in funding to the Department of Biochemistry and Molecular Biology, Faculty of Medicine at Dalhousie University, for a research project led by Dr. Paola Marignani.
[The Breast Cancer Society of Canada] |
|
|
|
|
| December 8 – 10, 2022
Los Angeles, California, United States |
|
|
|
|
|
| | Institute of Cancer Research – London, England, United Kingdom |
|
|
|
| | University of Vermont – Burlington, Vermont, United States |
|
|
|
| | Francis Crick Institute – London, England, United Kingdom |
|
|
|
| | University of California, San Francisco – San Francisco, California, United States |
|
|
|
| | German Cancer Research Center in the Helmholtz Association – Heidelberg, Germany |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
